Related Experiment Video
Updated: May 17, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
The requirement for cyclin D function in tumor maintenance
Yoon Jong Choi1, Xiaoyu Li, Per Hydbring
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Abstract:
D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains that allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals' health. Ablation of cyclin D3 in mice bearing Notch1-driven T cell acute lymphoblastic leukemias (T-ALL) triggered tumor cell apoptosis. Such selective killing of leukemic cells can also be achieved by inhibiting cyclin D associated kinase activity in mouse and human T-ALL models. Inhibition of cyclin D-kinase activity represents a highly-selective anticancer strategy that specifically targets cancer cells without significantly affecting normal tissues.
Insights
Targeting D-cyclins (cell cycle regulators) offers a selective cancer treatment. Inhibiting cyclin D-kinase activity induces tumor cell senescence or apoptosis, sparing healthy tissues.
Area of Science:
- Cell Biology
- Molecular Oncology
- Cancer Therapeutics
Background:
- D-cyclins are key regulators of the cell cycle.
- Targeting cell cycle machinery is a strategy for cancer treatment.
- Developing selective anticancer therapies is crucial.
Purpose of the Study:
- To evaluate the therapeutic potential of targeting D-cyclins in cancer.
- To assess the efficacy of D-cyclin ablation or inhibition in vivo.
- To determine the selectivity of D-cyclin-targeted therapies on cancer cells versus normal tissues.
Main Methods:
- Engineered mouse models for acute, global ablation of individual D-cyclins.
- Utilized ErbB2-driven mammary carcinoma and Notch1-driven T cell acute lymphoblastic leukemia (T-ALL) models.
- Inhibited cyclin D-associated kinase activity in cancer models.
Main Results:
- Shutdown of cyclin D1 induced tumor cell senescence in mammary carcinomas without adverse effects.
- Ablation of cyclin D3 triggered apoptosis in T-ALL cells.
- Inhibition of cyclin D-kinase activity selectively killed leukemic cells in mouse and human T-ALL models.
Conclusions:
- Inhibition of cyclin D-kinase activity is a highly selective anticancer strategy.
- This approach specifically targets cancer cells while sparing normal tissues.
- Targeting D-cyclins represents a promising therapeutic avenue for certain cancers.
More Related Videos
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Positive Regulator Molecules
Positive Regulator Molecules
Anaphase Promoting Complex
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...